ArticleFrontiers in immunology2026
Satralizumab in the management of aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder during pregnancy: a case report.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report the case of a 25-year-old pregnant woman who was diagnosed with aquaporin-4 antibody-positive (AQP4+) neuromyelitis optica spectrum disorder (NMOSD) at 19 weeks of gestation. During the acute stage of the disease, she was treated with high-dose prednisone pulse therapy. Beginning in the fourth week after disease onset, satralizumab was introduced as an adjunctive therapy, which enabled the progressive reduction and eventual discontinuation of corticosteroids. Subsequent follow-up showed marked improvement in visual field defect, successful spontaneous delivery, stable maternal condition, and transient early neonatal complications with favorable short-term recovery. This represents the first reported case in China of a patient diagnosed with AQP4 + NMOSD during pregnancy who was treated with satralizumab. This case provides additional clinical evidence to inform therapeutic decision-making for NMOSD occurring in pregnancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.